Immunostimulants drugs - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.94 [0.87, 1.02]< 14%26 studies (26/-)93.6 %some concerncritical moderatecrucial-
deaths 0.94 [0.89, 1.00]< 10%39 studies (39/-)97.9 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.95 [0.63, 1.45]< 136%4 studies (4/-)58.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.90 [0.64, 1.27]< 10%3 studies (3/-)72.2 %some concernnot evaluable moderateimportant-
clinical improvement 1.30 [0.91, 1.87]> 157%7 studies (7/-)92.3 %some concernserious moderateimportant-
clinical improvement (14-day) 1.87 [0.57, 6.14]> 158%3 studies (3/-)84.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.61 [0.69, 3.76]> 174%3 studies (3/-)86.2 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.69 [0.97, 2.94]> 10%2 studies (2/-)96.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.56 [1.02, 2.39]> 149%5 studies (5/-)98.0 %some concernserious moderateimportant-
death or ventilation 0.95 [0.87, 1.03]< 159%6 studies (6/-)88.1 %some concernnot evaluable moderateimportant-
hospital discharge 1.07 [0.96, 1.21]> 163%5 studies (5/-)88.8 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.77 [0.56, 1.05]< 132%10 studies (10/-)95.2 %some concerncritical moderateimportant-
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %NAnot evaluable important-
viral clearance 3.87 [1.04, 14.37]> 176%5 studies (5/-)97.8 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.08 [0.07, 16.52]> 197%5 studies (5/-)52.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.59 [0.67, 3.76]> 173%4 studies (4/-)85.4 %some concernnot evaluable moderateimportant-
ICU admission 0.60 [0.36, 0.98]< 10%5 studies (5/-)97.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.24 [1.06, 1.45]< 10%6 studies (6/-)0.4 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %NAnot evaluable important-
adverse events 1.11 [0.89, 1.39]< 10%5 studies (5/-)16.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.